Company: SXTPW
Filing Date: 2025-06-06
Form Type: DRS
Source: 0001213900-25-052232
Chunk: 9

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-06-06
Form: DRS
Chunk 9
---
 either (i) the same dosing regimen employed in the commercial Arakoda product (in which case reference is
made to the “Arakoda regimen of Tafenoquine” or (ii) different dosing regimens (in which case reference is made to “Tafenoquine”).
We also utilize the molecular name (Tafenoquine), where the active ingredient of Arakoda and Kodatef was tested in cell culture or animal
models. These different usages have been employed both for convenience and to avoid any assertions that Arakoda or Kodatef have been granted
marketing authorization by regulators for uses other than the prevention of malaria.

<div align='center'>MARKET DATA</div>

Market data and certain industry data and forecasts
used throughout this prospectus were obtained from internal company surveys, market research, consultant surveys, publicly available information,
reports of governmental agencies and industry publications and surveys. Industry surveys, publications, consultant surveys and forecasts
generally state that the information contained therein has been obtained from sources believed to be reliable, but the accuracy and completeness
of such information is not guaranteed. Forecasts are particularly likely to be inaccurate, especially over long periods of time. In addition,
we do not necessarily know what assumptions regarding general economic growth were used in preparing the forecasts we cite. Statements
regarding our market position are based on the most currently available data. While we are not aware of any misstatements regarding the
industry data presented in this prospectus, our estimates involve risks and uncertainties and are subject to change based on various factors,
including those discussed under the heading “Risk Factors” in this prospectus.

<div align='center'>iv</div>

PROSPECTUS SUMMARY Our Business We are a specialty pharmaceutical company with a goal of using cutting-edge biological science and applied research to further develop and commercialize new therapies for the prevention and treatment of infectious diseases. We have successfully achieved regulatory approval of Arakoda, a malaria preventative treatment that has been on the market since late 2019. Currently, 60P’s pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company’s future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir/extracts of Australian Chestnut trees. Mission Our mission is to address the unmet medical need associated with infectious diseases through the development and commercialization